Sign Out
No concomitant immunization data are available either inside or outside of China for the product.
During the phase III clinical trial of the product, the interval between vaccination of the product and any other diphtheria, tetanus, and acellular pertussis (DTaP)-containing vaccine was ≥10 days. No adverse impact of DTaP-containing vaccine was observed on the immunogenicity of PCV13-TT under the indicated immunization interval.
Continue with Google